Published in J Urol on July 01, 2005
The neural control of micturition. Nat Rev Neurosci (2008) 4.19
Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol (2006) 1.94
Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med (2006) 1.94
Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol (2009) 1.63
Botulinum toxin A: First-line therapy for idiopathic detrusor overactivity. Can Urol Assoc J (2011) 1.47
Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol (2009) 1.42
Role of gap junctions in spontaneous activity of the rat bladder. Am J Physiol Renal Physiol (2007) 1.36
Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol (2009) 1.22
Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol (2010) 1.00
Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol (2008) 1.00
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol (2012) 0.93
Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol (2010) 0.92
OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology (2013) 0.92
Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med (2008) 0.91
Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol (2014) 0.91
A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol (2009) 0.91
Botulinum toxin in neurogenic detrusor overactivity. Int Neurourol J (2012) 0.91
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol (2009) 0.91
Alternative approaches to sacral nerve stimulation. Int Urogynecol J (2010) 0.90
Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol (2006) 0.90
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med (2013) 0.89
What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU? Cent European J Urol (2014) 0.86
The use of botulinum neurotoxin type A (BoNTA) in urology. J Neural Transm (Vienna) (2008) 0.84
Evaluation and Management of Neurogenic Bladder: What Is New in China? Int J Mol Sci (2015) 0.83
Neurogenic bladder in spinal cord injury patients. Res Rep Urol (2015) 0.82
Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol (2008) 0.82
Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.82
Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity. J Exerc Rehabil (2016) 0.81
Current and potential urological applications of botulinum toxin A. Nat Rev Urol (2015) 0.80
Botulinum toxin in paediatric urology: a systematic literature review. Pediatr Surg Int (2008) 0.79
Radiofrequency sacral rhizotomy for the management of intolerable neurogenic bladder in spinal cord injured patients. Ann Rehabil Med (2012) 0.79
Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol (2012) 0.79
Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity. Nephrourol Mon (2012) 0.79
Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl) (2015) 0.79
Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury. J Neurotrauma (2016) 0.78
Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients? Transl Androl Urol (2015) 0.78
Botulinum toxin in multiple sclerosis. J Neurol (2006) 0.78
The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA. Urol Ann (2015) 0.78
OnabotulinumtoxinA in the treatment of neurogenic bladder. Biologics (2012) 0.78
Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol (2016) 0.78
Systematic review of overactive bladder therapy in females. Can Urol Assoc J (2011) 0.78
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. Int Braz J Urol (2015) 0.77
Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. World J Urol (2011) 0.77
Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol (2016) 0.77
Emerging treatments for overactive bladder: clinical potential of botulinum toxins. Res Rep Urol (2014) 0.77
Can the ice-water test predict the outcome of intradetrusor injections of botulinum toxin in patients with neurogenic bladder dysfunction? World J Urol (2007) 0.76
Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. ScientificWorldJournal (2012) 0.76
How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? World J Nephrol (2016) 0.75
Botulinum toxin A for the Treatment of Overactive Bladder. Toxins (Basel) (2016) 0.75
Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep (2016) 0.75
Intravesical Botulinum Toxin for Persistent Autonomic Dysreflexia in a Pediatric Patient. Case Rep Urol (2016) 0.75
The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol (2016) 0.75
Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: impact on the quality of life of patients with SCI. Spinal Cord (2016) 0.75
Hematuria following Botox treatment for upper limb spasticity: a case report. J Pain Res (2015) 0.75
Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. Int Neurourol J (2017) 0.75
Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. Toxins (Basel) (2015) 0.75
The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol (2013) 0.75
Modeling of chronic radiation-induced cystitis in mice. Adv Radiat Oncol (2016) 0.75
Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms. Investig Clin Urol (2016) 0.75
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins (Basel) (2016) 0.75
Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2016) 0.75
Is botulinum toxin type A a safe and effective treatment for neurogenic urinary incontinence? Nat Clin Pract Urol (2005) 0.75
Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport(®)) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? Toxins (Basel) (2015) 0.75
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. Urol Clin North Am (2017) 0.75
Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. Curr Urol Rep (2017) 0.75
Botulinum Toxin Treatment in Multiple Sclerosis-a Review. Curr Treat Options Neurol (2017) 0.75
Neural control of lower urinary tract and targets for pharmacological therapy. Int Urogynecol J (2014) 0.75
Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults. World J Urol (2011) 0.75
Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity. World J Urol (2015) 0.75
Use of botulinum toxin for voiding dysfunction. Transl Androl Urol (2017) 0.75
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 4.37
Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol (2008) 3.09
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow-up. Eur Urol (2012) 2.43
The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int (2005) 2.31
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29
Laparoscopic approach for artificial urinary sphincter implantation in women with intrinsic sphincter deficiency incontinence: a single-centre preliminary experience. Eur Urol (2009) 2.18
Ejaculation elicited by microstimulation of lumbar spinothalamic neurons. Eur Urol (2008) 2.10
Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience. J Urol (2012) 2.08
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol (2007) 2.04
Involvement of connexins 43 and 45 in functional mechanism of human detrusor overactivity in neurogenic bladder. Urology (2013) 2.01
Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol (2007) 1.79
MicroRNAs in gene regulation: when the smallest governs it all. J Biomed Biotechnol (2006) 1.76
Testicular cancer variations in time and space in Europe. Eur Urol (2006) 1.67
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol (2012) 1.61
Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol (2007) 1.53
European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol (2004) 1.49
Arachnoiditis ossificans of the cauda equina. Case report and review of the literature. J Neurosurg (2002) 1.47
A method to assess seasonality of urinary tract infections based on medication sales and google trends. PLoS One (2013) 1.46
[Partial nephrectomy by selective renal parenchymal clamping using a new clamp]. Prog Urol (2007) 1.45
Impact of diagnostic delay in testis cancer: results of a large population-based study. Eur Urol (2007) 1.44
Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). Eur Urol (2006) 1.43
Long-term functional outcomes after artificial urinary sphincter implantation in women with stress urinary incontinence. BJU Int (2014) 1.42
[Efficacy and safety of Pelvicol in the vaginal treatment of prolapse]. Prog Urol (2006) 1.42
Retroperitoneoscopic adrenalectomy: comparison of retrograde and antegrade approach among a series of 279 cases. Urology (2013) 1.40
OnabotulinumtoxinA treatment of mild glabellar lines in repose. Dermatol Surg (2010) 1.40
[Hospital intern, what title for which training?]. Presse Med (2002) 1.39
[Can a standard treatment be proposed for penile cancer?]. Prog Urol (2007) 1.39
[Role of endoscopy in the management of upper urinary tract tumors]. Prog Urol (2006) 1.39
Conservative management of small testicular tumors relative to carcinoma in situ prevalence. J Urol (2005) 1.39
The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler (2007) 1.38
Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol (2008) 1.35
High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int (2008) 1.34
The AdVance transobturator male sling for postprostatectomy incontinence: clinical results of a prospective evaluation after a minimum follow-up of 6 months. Eur Urol (2009) 1.32
Urinary incontinence in French women: prevalence, risk factors, and impact on quality of life. Eur Urol (2009) 1.30
Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int (2006) 1.26
Polyorchidism: presentation of 2 cases, review of the literature and a new management strategy. Urol Int (2008) 1.20
Late metastasis of renal cell carcinoma to the submaxillary gland 10 years after radical nephrectomy. Int J Urol (2006) 1.19
Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord (2010) 1.15
Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil (2007) 1.13
Midterm prospective evaluation of TVT-Secur reveals high failure rate. Eur Urol (2010) 1.13
Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence: results from PURE. Eur Urol (2006) 1.11
Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. BJU Int (2010) 1.09
Effects of potassium channel modulators on myogenic spontaneous phasic contractile activity in human detrusor from neurogenic patients. BJU Int (2010) 1.09
Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn (2011) 1.08
Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Ann Neurol (2002) 1.06
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int (2005) 1.06
Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool. BMC Neurol (2013) 1.05
Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC beta-lactamase in a teaching hospital admitting disabled patients. Antimicrob Agents Chemother (2005) 1.04
Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology (2006) 1.04
Mapping of transrectal ultrasonographic prostate biopsies: quality control and learning curve assessment by image processing. J Ultrasound Med (2009) 1.03
Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol (2006) 1.02
Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol (2009) 1.02
Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch (2005) 1.01
Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol (2012) 0.99
Laparoscopic excision of seminal vesicle cyst revealed by obstruction urinary symptoms. Int J Urol (2006) 0.98
A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn (2013) 0.98
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther (2007) 0.98
Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn (2010) 0.98
Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robot-assisted radical prostatectomy for localized prostate cancer. World J Urol (2009) 0.98
A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol (2002) 0.97
CT diagnosis of ureteral fibroepithelial polyps. Eur Radiol (2001) 0.97
Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg (2005) 0.96
Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int (2007) 0.96
How urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological association. J Sex Med (2007) 0.96
A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. Urol Oncol (2011) 0.95
Long-term functional outcomes after ileal ureter substitution: a single-center experience. Urology (2011) 0.94
[Epidemiology of urological emergencies in a teaching hospital]. Prog Urol (2002) 0.94
The safety of the inside-out transobturator approach for transvaginal tape (TVT-O) treatment in stress urinary incontinence: French registry data on 984 women. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.94
Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol (2011) 0.93
Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia. Mov Disord (2010) 0.93
Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose. Eur J Nucl Med Mol Imaging (2011) 0.93
Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil (2006) 0.92
Adrenal tumours are more predominant in females regardless of their histological subtype: a review. World J Urol (2013) 0.91
Corticospinal excitability accompanying ballistic wrist movements in primary dystonia. Mov Disord (2004) 0.91
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol (2011) 0.91
Respiratory effects of combined truncal and abdominal support in patients with spinal cord injury. Arch Phys Med Rehabil (2005) 0.90
Induction of spermatogenesis in azoospermic men after internal spermatic vein embolization for the treatment of varicocele. Hum Reprod (2004) 0.90
Rehabilitation in practice: neurogenic lower urinary tract dysfunction and its management. Clin Rehabil (2010) 0.90
Laparoscopic surgical complete sling resection for tension-free vaginal tape-related complications refractory to first-line conservative management: a single-centre experience. Eur Urol (2010) 0.89
[Bladder cancer in neurological patients: analysis of a single-centre series]. Prog Urol (2007) 0.89
Impact of elective versus imperative indications on oncologic outcomes after open nephron-sparing surgery for the treatment of sporadic renal cell carcinomas. Ann Surg Oncol (2010) 0.89
[Prospective evaluation of the effects of a practical introduction to urology session on the recruitment of urology intern in Paris: final results]. Prog Urol (2007) 0.89
Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. Mov Disord (2008) 0.89
Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol (2004) 0.89